Hansa Biopharma HNSA.ST · SEK

Its shares trade on Nasdaq Stockholm under the ticker HNSA.ST. It has been listed since 17 October 2007. In the fiscal year to 31 December 2025, it reported revenue of SEK 222.3m and a net loss of SEK 534.1m. At that date it held total assets of SEK 1.17bn and shareholders' equity of −SEK 89.0m.

Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treats rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. The company is headquartered in Lund, Skane. The company went IPO on 2007-10-17. The Company’s operations consist of research and development for drug discovery. The firm conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Peter NicklinIndependent Chairman of the BoardSEK 1.2m
• Ms. Renee Aguiar - LucanderChief Executive Officer
• Mr. Evan BallantyneChief Financial Officer, Senior Vice President
• Ms. Maria TornsenChief Operating Officer and President of United State
• Ms. Sandra FrithiofChief Human Resources Officer
• Dr. Hitto KaufmannSenior Vice President, Chief R&D Officer
• Dr. Richard PhilipsonChief Medical Officer
• Ms. Natalie BernerDirector
• Dr. Elisabeth BjorkIndependent Director
• Mr. Mats BlomIndependent DirectorSEK 494,000
• Mr. Michael BolognaIndependent Director
• Ms. Hilary MaloneIndependent DirectorSEK 871,000

Overall

63

Environment

30

Social

96

Governance

63

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.